Positive data from trial of OPC 34712 for MDD - Otsuka/Lundbeck
Phase III data on OPC 34712 (brexpiprazole), from Otsuka and Lundbeck, as adjunctive therapy to antidepressant therapy in patients with Major Depressive Disorder (MDD) shows brexpiprazole demonstrated efficacy and was well tolerated. The study showed statistically significant improvements in mean MADRS total score for patients receiving adjunctive brexpiprazole compared with placebo and a statistically significant advantage over placebo on all secondary endpoints.
Most common adverse events reported in the patients receiving adjunctive brexpiprazole were weight gain and akathisia (inner restlessness). Three additional studies in Depression and Schizophrenia will conclude in the first half of 2014. Results will be presented at an upcoming poster session at the 22nd European Psychiatry Association Congress.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.